Sign inJoin waitlistJoin the waitlist

Zaid Al-Kadhimi

Physician · UAB Heersink School of Medicine

Credentials: · · · · · · ·

History

UAB Heersink School of Medicine
2023–Present

Hematology
1994–1995
Internal Medicine
Henry Ford Health
1991–1994
University of Baghdad College of Medicine
1987–1991

Research

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus…
The Lancet Haematology · 2019 · 246 citations
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A…
Transplantation and Cellular Therapy · 2021 · 172 citations
Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial
Clinical Cancer Research · 2015 · 90 citations

Lawrence Lum
19 papers
Joseph Uberti
18 papers
VR
Voravit Ratanatharathorn
16 papers
Abinhav Deol
15 papers
Lois Ayash
15 papers
Krishna Gundabolu
9 papers
LM
Lori Maness-Harris
9 papers
Vijaya Bhatt
9 papers
Edmund Waller
7 papers
Stephen Forman
6 papers
Zartash Gul
6 papers
Amelia Langston
5 papers

Grants

BMT Core: Southeast Bone Marrow Transplant Consortium
National Heart, Lung, and Blood Institute · UG1
PI · $712.8K · Emory University
2024–2031

Clinical trials

Donor Enriched Activated NK Cell Infusion Post Haploidentical Stem Cell Transplant for Refractory Myeloid Malignancies
Principal investigator · Withdrawn · Phase 1
University of Nebraska
2023
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Principal investigator · Terminated · Phase 2
Emory University
2016–2017
High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant
Principal investigator · Terminated · Phase 2
Barbara Ann Karmanos Cancer Institute
2012–2013
Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
Principal investigator · Completed · Phase 2
Barbara Ann Karmanos Cancer Institute
2010–2013